Literature DB >> 27975141

Glucose and angiotensin II-derived endothelial extracellular vesicles regulate endothelial dysfunction via ERK1/2 activation.

Kumiko Taguchi1, Mari Hida1, Haruka Narimatsu1, Takayuki Matsumoto1, Tsuneo Kobayashi2.   

Abstract

In various diseases, including diabetes, extracellular vesicles (EVs) have been detected in circulation and tissues. EVs are small membrane vesicles released from various cell types under varying conditions. Recently, endothelial cell-derived EVs (EEVs) were identified as a marker of endothelial dysfunction in diabetes, but the ensuing mechanisms remain poorly understood. In this study, we dissected the ensuing pathways with respect to nitric oxide (NO) production under the condition of type 2 diabetes. Human umbilical vein endothelial cells (HUVECs) were stimulated with glucose alone and with glucose in combination with angiotensin II (Ang II) for 48 h. In supernatants from glucose + Ang II-stimulated HUVECs, release of EEVs was assessed using Western blotting with an anti-CD144 antibody. EEV release was significantly increased after stimulation of HUVECs, and high glucose + Ang II-derived EEVs impaired ACh-induced vascular relaxation responses and NO production in mice aortic rings. Furthermore, high glucose + Ang II-derived EEVs induced ERK1/2 signalling and decreased endothelial NO synthase (eNOS) protein expression in mice aortas. Furthermore, in the presence of the MEK/ERK1/2 inhibitor PD98059, high glucose plus Ang II treatment stimulated EEVs in HUVECs and those EEVs prevented the impairments of ACh-induced relaxation and NO production in mice aortas. These data strongly indicate that high glucose and Ang II directly affect endothelial cells and the production of EEVs; the resultant EEVs aggravate endothelial dysfunction by regulating eNOS protein levels and ERK1/2 signalling in mice aortas.

Entities:  

Keywords:  ERK1/2; Endothelial dysfunction; Extracellular vesicle; No; eNOS

Mesh:

Substances:

Year:  2016        PMID: 27975141     DOI: 10.1007/s00424-016-1926-2

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  53 in total

1.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.

Authors:  Nicolas Amabile; Alain P Guérin; Aurélie Leroyer; Ziad Mallat; Clément Nguyen; Jacques Boddaert; Gérard M London; Alain Tedgui; Chantal M Boulanger
Journal:  J Am Soc Nephrol       Date:  2005-09-28       Impact factor: 10.121

Review 2.  Microparticles as biomarkers of vascular dysfunction in metabolic syndrome and its individual components.

Authors:  Abdelali Agouni; Ramaroson Andriantsitohaina; Maria C Martinez
Journal:  Curr Vasc Pharmacol       Date:  2014-05       Impact factor: 2.719

3.  Paradoxical overexpression and translocation of connexin43 in homocysteine-treated endothelial cells.

Authors:  Hong Li; Sergey Brodsky; Sindu Kumari; Virginijus Valiunas; Peter Brink; Jun-Ichi Kaide; Alberto Nasjletti; Michael S Goligorsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06       Impact factor: 4.733

Review 4.  Extracellular vesicles as new pharmacological targets to treat atherosclerosis.

Authors:  Min Yin; Xavier Loyer; Chantal M Boulanger
Journal:  Eur J Pharmacol       Date:  2015-07-02       Impact factor: 4.432

5.  Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Hidenobu Koga; Seigo Sugiyama; Kiyotaka Kugiyama; Keisuke Watanabe; Hironobu Fukushima; Tomoko Tanaka; Tomohiro Sakamoto; Michihiro Yoshimura; Hideaki Jinnouchi; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

6.  Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease.

Authors:  Nikos Werner; Sven Wassmann; Patrick Ahlers; Sonja Kosiol; Georg Nickenig
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-20       Impact factor: 8.311

7.  High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation.

Authors:  Felix Jansen; Xiaoyan Yang; Bernardo S Franklin; Marion Hoelscher; Theresa Schmitz; Jörg Bedorf; Georg Nickenig; Nikos Werner
Journal:  Cardiovasc Res       Date:  2013-01-22       Impact factor: 10.787

Review 8.  Cellular microparticles: new players in the field of vascular disease?

Authors:  M Diamant; M E Tushuizen; A Sturk; R Nieuwland
Journal:  Eur J Clin Invest       Date:  2004-06       Impact factor: 4.686

Review 9.  Endothelial function: a critical determinant in atherosclerosis?

Authors:  Ulf Landmesser; Burkhard Hornig; Helmut Drexler
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

10.  Type 1 and type 2 diabetic patients display different patterns of cellular microparticles.

Authors:  Florence Sabatier; Patrice Darmon; Benedicte Hugel; Valery Combes; Marielle Sanmarco; Jean-Gabriel Velut; Dominique Arnoux; Phillipe Charpiot; Jean-Marie Freyssinet; Charles Oliver; Jose Sampol; Francoise Dignat-George
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

View more
  11 in total

Review 1.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 2.  Extracellular vesicles in autoimmune vasculitis - Little dirts light the fire in blood vessels.

Authors:  Xiuhua Wu; Yu Liu; Wei Wei; Ming-Lin Liu
Journal:  Autoimmun Rev       Date:  2019-04-05       Impact factor: 9.754

3.  Factor VIIa suppresses inflammation and barrier disruption through the release of EEVs and transfer of microRNA 10a.

Authors:  Kaushik Das; Shiva Keshava; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2022-01-06       Impact factor: 22.113

Review 4.  Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage.

Authors:  Fabrizio Buffolo; Silvia Monticone; Giovanni Camussi; Elena Aikawa
Journal:  Hypertension       Date:  2022-02-11       Impact factor: 9.897

Review 5.  Extracellular vesicles in vascular remodeling.

Authors:  Chao Ye; Fen Zheng; Nan Wu; Guo-Qing Zhu; Xiu-Zhen Li
Journal:  Acta Pharmacol Sin       Date:  2022-01-12       Impact factor: 7.169

Review 6.  Endothelial response to glucose: dysfunction, metabolism, and transport.

Authors:  Alisa Morss Clyne
Journal:  Biochem Soc Trans       Date:  2021-02-26       Impact factor: 5.407

7.  Alteration of Vascular Responsiveness to Uridine Adenosine Tetraphosphate in Aortas Isolated from Male Diabetic Otsuka Long-Evans Tokushima Fatty Rats: The Involvement of Prostanoids.

Authors:  Takayuki Matsumoto; Shota Kobayashi; Makoto Ando; Maika Iguchi; Keisuke Takayanagi; Mihoka Kojima; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Int J Mol Sci       Date:  2017-11-09       Impact factor: 5.923

8.  Apoptotic exosome-like vesicles regulate endothelial gene expression, inflammatory signaling, and function through the NF-κB signaling pathway.

Authors:  Francis Migneault; Mélanie Dieudé; Julie Turgeon; Déborah Beillevaire; Marie-Pierre Hardy; Alexandre Brodeur; Nicolas Thibodeau; Claude Perreault; Marie-Josée Hébert
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

9.  Different Calcium and Src Family Kinase Signaling in Mac-1 Dependent Phagocytosis and Extracellular Vesicle Generation.

Authors:  Ákos M Lőrincz; Viktória Szeifert; Balázs Bartos; Dávid Szombath; Attila Mócsai; Erzsébet Ligeti
Journal:  Front Immunol       Date:  2019-12-17       Impact factor: 7.561

10.  Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy.

Authors:  Yi Wang; Zhiheng Guo; Yongmei Gao; Ping Liang; Yanhong Shan; Jin He
Journal:  Cell Biosci       Date:  2019-10-21       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.